Literature DB >> 33219855

Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).

Theresa Steeb1,2, Anja Wessely1,2, Max Schlaak3, Markus V Heppt1,2, Mareike Alter4, Christiane Bayerl5, Armin Bender6, Guido Bruning7, Evelyn Dabrowski8, Dirk Debus9, Nina Devereux7, Edgar Dippel8, Konstantin Drexler10, Pia Dücker11, Reinhard Dummer12, Steffen Emmert13, Peter Elsner14, Alexander Enk15, Christoffer Gebhardt16, Anja Gesierich17, Matthias Goebeler17, Sergij Goerdt18, Steven Goetze14, Ralf Gutzmer19, Sebastian Haferkamp10, Gesina Hansel20, Jessica C Hassel15, Lucie Heinzerling1,2,21, Katharina C Kähler22, Kjell M Kaume23, Wolfgang Krapf24, Nicole Kreuzberg25, Percy Lehmann26, Elisabeth Livingstone27, Harald Löffler24, Carmen Loquai28, Cornelia Mauch25, Johanna Mangana12, Friedegund Meier29, Markus Meissner30, Rose K C Moritz31, Lara Valeska Maul32, Verena Müller18, Peter Mohr33, Alexander Navarini32, Ahn Van Nguyen34, Christiane Pfeiffer35,36, Claudia Pföhler37, Christian Posch38, Erika Richtig39, Rainer Rompel40, Michael M Sachse41, Stefanie Sauder40, Dirk Schadendorf27, Kerstin Schatton42, Hans-Joachim Schulze43, Erwin Schultz9, Bastian Schilling17, Matthias Schmuth34, Jan C Simon44, Markus Streit45, Patrick Terheyden46, Alexander Thiem13, Thomas Tüting4, Julia Welzel35, Gerhard Weyandt47, Ulrich Wesselmann26, Uwe Wollina20, Mirjana Ziemer44, Lisa Zimmer27, Markus Zutt23, Carola Berking1,2.   

Abstract

PURPOSE: Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance remain unclear as they are situated in an interdisciplinary setting.
METHODS: A questionnaire addressing the patterns of care and surveillance in the management of patients with uveal melanoma was distributed to 70 skin cancer centers in Austria, Germany and Switzerland. Frequency distributions of responses for each item of the questionnaire were calculated.
RESULTS: 44 of 70 (62.9%) skin cancer centers completed the questionnaire. Thirty-nine hospitals were located in Germany (88.6%), three in Switzerland (6.8%) and two in Austria (4.5%). The majority (68.2%) represented university hospitals. Most patients with metastatic disease were treated in certified skin cancer centers (70.7%, 29/41). Besides, the majority of patients with UM were referred to the respective skin cancer center by ophthalmologists (87.2%, 34/39). Treatment and organization of follow-up of patients varied across the different centers. 35.1% (14/37) of the centers stated to not perform any screening measures.
CONCLUSION: Treatment patterns of patients with uveal melanoma in Germany, Austria and Switzerland remain extremely heterogeneous. A guideline for the treatment and surveillance is urgently needed.

Entities:  

Keywords:  Background; Cross-sectional study; Follow-up; Ocular melanoma; Patterns of care; Surveillance; Treatment patterns; Uveal melanoma

Year:  2020        PMID: 33219855     DOI: 10.1007/s00432-020-03450-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  17 in total

Review 1.  Metastatic uveal melanoma therapy: current options.

Authors:  Agop Y Bedikian
Journal:  Int Ophthalmol Clin       Date:  2006

Review 2.  [Management of uveal melanomas, guidelines for oncologists].

Authors:  Thibaud Mathis; Nathalie Cassoux; Magali Tardy; Sophie Piperno; Lauris Gastaud; Rémi Dendale; Celia Maschi; Anh-Minh Nguyen; Laurent Meyer; Nicolas Bonnin; Stephanie Baillif; Sarah Tick; Fréderic Mouriaux; Franck Jaspart; Josette Dellis; Laurence Rosier; Laurence Desjardins; Joel Herault; Jean Pierre Caujolle; Juliette Thariat
Journal:  Bull Cancer       Date:  2018-09-11       Impact factor: 1.276

3.  S3-Leitlinie Diagnostik, Therapie und Nachsorge des Melanoms - Update 2015/2016, Kurzversion 2.0.

Authors:  Thomas K Eigentler; Corinna Mühlenbein; Markus Follmann; Dirk Schadendorf; Claus Garbe
Journal:  J Dtsch Dermatol Ges       Date:  2017-06       Impact factor: 5.584

4.  Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe.

Authors:  S Mallone; E De Vries; M Guzzo; E Midena; J Verne; J W Coebergh; R Marcos-Gragera; E Ardanaz; R Martinez; M D Chirlaque; C Navarro; G Virgili
Journal:  Eur J Cancer       Date:  2011-11-25       Impact factor: 9.162

5.  Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.

Authors:  Markus V Heppt; Lucie Heinzerling; Katharina C Kähler; Andrea Forschner; Michael C Kirchberger; Carmen Loquai; Markus Meissner; Friedegund Meier; Patrick Terheyden; Beatrice Schell; Rudolf Herbst; Daniela Göppner; Felix Kiecker; David Rafei-Shamsabadi; Sebastian Haferkamp; Margit A Huber; Jochen Utikal; Mirjana Ziemer; Irmgard Bumeder; Christiane Pfeiffer; Susanne G Schäd; Christoph Schmid-Tannwald; Julia K Tietze; Thomas K Eigentler; Carola Berking
Journal:  Eur J Cancer       Date:  2017-06-22       Impact factor: 9.162

Review 6.  Uveal melanoma: From diagnosis to treatment and the science in between.

Authors:  Chandrani Chattopadhyay; Dae Won Kim; Dan S Gombos; Junna Oba; Yong Qin; Michelle D Williams; Bita Esmaeli; Elizabeth A Grimm; Jennifer A Wargo; Scott E Woodman; Sapna P Patel
Journal:  Cancer       Date:  2016-03-15       Impact factor: 6.860

Review 7.  Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review.

Authors:  Markus V Heppt; Theresa Steeb; Justin Gabriel Schlager; Stefanie Rosumeck; Corinna Dressler; Thomas Ruzicka; Alexander Nast; Carola Berking
Journal:  Cancer Treat Rev       Date:  2017-08-24       Impact factor: 12.111

8.  Monoclonal TCR-redirected tumor cell killing.

Authors:  Nathaniel Liddy; Giovanna Bossi; Katherine J Adams; Anna Lissina; Tara M Mahon; Namir J Hassan; Jessie Gavarret; Frayne C Bianchi; Nicholas J Pumphrey; Kristin Ladell; Emma Gostick; Andrew K Sewell; Nikolai M Lissin; Naomi E Harwood; Peter E Molloy; Yi Li; Brian J Cameron; Malkit Sami; Emma E Baston; Penio T Todorov; Samantha J Paston; Rebecca E Dennis; Jane V Harper; Steve M Dunn; Rebecca Ashfield; Andy Johnson; Yvonne McGrath; Gabriela Plesa; Carl H June; Michael Kalos; David A Price; Annelise Vuidepot; Daniel D Williams; Deborah H Sutton; Bent K Jakobsen
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

9.  Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study.

Authors:  Markus V Heppt; Teresa Amaral; Katharina C Kähler; Lucie Heinzerling; Jessica C Hassel; Markus Meissner; Nicole Kreuzberg; Carmen Loquai; Lydia Reinhardt; Jochen Utikal; Evelyn Dabrowski; Anja Gesierich; Claudia Pföhler; Patrick Terheyden; Kai-Martin Thoms; Lisa Zimmer; Thomas K Eigentler; Michael C Kirchberger; Henner M Stege; Friedegund Meier; Max Schlaak; Carola Berking
Journal:  J Immunother Cancer       Date:  2019-11-13       Impact factor: 13.751

Review 10.  Metastatic disease from uveal melanoma: treatment options and future prospects.

Authors:  Richard D Carvajal; Gary K Schwartz; Tongalp Tezel; Brian Marr; Jasmine H Francis; Paul D Nathan
Journal:  Br J Ophthalmol       Date:  2016-08-29       Impact factor: 4.638

View more
  1 in total

1.  Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?

Authors:  Chiara L Blomen; Julian Kött; Tabea I Hartung; Leopold K Torster; Christoffer Gebhardt
Journal:  Cancers (Basel)       Date:  2021-12-20       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.